Milk Thistle and Losartan Interaction
Milk thistle (silymarin) inhibits the metabolism of losartan to its active metabolite E-3174, potentially reducing losartan's antihypertensive efficacy, particularly in patients with normal CYP2C9 enzyme function.
Mechanism of Interaction
The interaction occurs through CYP2C9 enzyme inhibition. Losartan is a prodrug that requires conversion to its active metabolite E-3174 via CYP2C9 for full therapeutic effect 1. When silymarin is co-administered:
- *In CYP2C91/*1 (normal metabolizers)**: Silymarin significantly increases losartan AUC while decreasing E-3174 AUC, with a significant reduction in the metabolic ratio (p < 0.05) 1
- *In CYP2C91/*3 (intermediate metabolizers)**: The effect is less pronounced, with decreased E-3174 formation but no significant change in metabolic ratio (p = 0.065) 1
This represents a pharmacokinetic interaction where silymarin blocks the conversion of inactive losartan to active E-3174, potentially compromising blood pressure control.
Clinical Significance
The interaction is clinically relevant and warrants caution. While some guidelines mention milk thistle as contraindicated with simeprevir 2, the specific losartan interaction data comes from controlled pharmacokinetic studies 1. The FDA label for losartan does not specifically list milk thistle as an interaction 3, but it does note that CYP2C9 inhibitors can affect losartan metabolism 3.
Importantly, broader systematic reviews have found that most in vivo human studies show no clinically significant silymarin-drug interactions 4, and a 14-day study with standardized milk thistle extract showed no significant effect on CYP2C9 activity using tolbutamide as a probe drug 5. This apparent contradiction likely reflects:
- Differences in silymarin formulations and doses
- The specific sensitivity of losartan as a CYP2C9 substrate
- Individual genetic variability in CYP2C9 function
Practical Management
Monitor blood pressure closely if patients insist on combining these agents:
- Check blood pressure 1-2 weeks after starting milk thistle
- Consider increasing losartan dose if blood pressure rises (maximum 100 mg daily, or 150 mg for heart failure per HEAAL trial data 6, 7)
- Alternatively, switch to an ARB less dependent on CYP2C9 metabolism (e.g., valsartan, which showed non-inferiority to captopril 8)
- For patients with CYP2C9*1/*3 genotype, the interaction may be less pronounced but still warrants monitoring 1
Ideally, advise discontinuation of milk thistle during losartan therapy, especially in patients with:
- Difficult-to-control hypertension
- Left ventricular hypertrophy (where losartan's specific benefits are important 9)
- Diabetic nephropathy (where optimal ARB dosing is critical 10)
Important Caveats
The interaction study used 140 mg silymarin three times daily for 14 days 1—doses and durations may vary with commercial products. Milk thistle supplements are not FDA-regulated, so silymarin content varies considerably between preparations (typically 70-80% silymarin, but inconsistent) 11.
The postpartum hypertension guideline lists losartan as having "limited safety data" with an RID of 0.9%-7.1% in breastmilk 12, which is a separate consideration from the drug interaction but relevant for comprehensive patient counseling.